US Patent

US9334305 — Synthetic peptide amides and dimers thereof

Method of Use · Assigned to Cara Therapeutics Inc · Expires 2027-11-12 · 1y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects synthetic peptide amide ligands that activate the kappa opioid receptor with low potential for liver enzyme inhibition and brain penetration.

USPTO Abstract

The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P 450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3204 — difelikefalin-acetate

Patent Metadata

Patent number
US9334305
Jurisdiction
US
Classification
Method of Use
Expires
2027-11-12
Drug substance claim
No
Drug product claim
No
Assignee
Cara Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.